MTR 104

Drug Profile

MTR 104

Alternative Names: Difetur; MTR 104; MTR 105; MTR 106; MTR 107; Nitric oxide synthase inhibitors - Meditor

Latest Information Update: 28 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meditor Pharmaceuticals
  • Class Antihypotensives; Antimigraines; Urea compounds
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypotension
  • Discontinued Migraine

Most Recent Events

  • 11 Jun 2008 Final efficacy data from a phase II trial in Migraine released by Meditor
  • 09 Nov 2007 Results from a phase II clinical trial in patients with Migraine added to the adverse events and Advances in the Treatment of Nausea and Migraine therapeutic trials sections
  • 04 Oct 2006 MTR 107 is available for licensing and development partners (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top